ID   DSRAD_RAT               Reviewed;        1175 AA.
AC   P55266;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   24-JAN-2024, entry version 154.
DE   RecName: Full=Double-stranded RNA-specific adenosine deaminase;
DE            Short=DRADA;
DE            EC=3.5.4.37;
GN   Name=Adar; Synonyms=Dsrad;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   STRAIN=Wistar; TISSUE=Brain;
RX   PubMed=7862132; DOI=10.1128/mcb.15.3.1389;
RA   O'Connell M.A., Krause S., Higuchi M., Hsuan J.J., Totty N.F., Jenny A.,
RA   Keller W.;
RT   "Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine
RT   deaminase.";
RL   Mol. Cell. Biol. 15:1389-1397(1995).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-228 AND SER-235, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Catalyzes the hydrolytic deamination of adenosine to inosine
CC       in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This
CC       may affect gene expression and function in a number of ways that
CC       include mRNA translation by changing codons and hence the amino acid
CC       sequence of proteins; pre-mRNA splicing by altering splice site
CC       recognition sequences; RNA stability by changing sequences involved in
CC       nuclease recognition; genetic stability in the case of RNA virus
CC       genomes by changing sequences during viral RNA replication; and RNA
CC       structure-dependent activities such as microRNA production or targeting
CC       or protein-RNA interactions. Can edit both viral and cellular RNAs and
CC       can edit RNAs at multiple sites (hyper-editing) or at specific sites
CC       (site-specific editing). Its cellular RNA substrates include: bladder
CC       cancer-associated protein (BLCAP), neurotransmitter receptors for
CC       glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3).
CC       Site-specific RNA editing of transcripts encoding these proteins
CC       results in amino acid substitutions which consequently alters their
CC       functional activities. Exhibits low-level editing at the GRIA2 Q/R
CC       site, but edits efficiently at the R/G site and HOTSPOT1. Does not
CC       affect polyomavirus replication but provides protection against virus-
CC       induced cytopathic effects. Essential for embryonic development and
CC       cell survival and plays a critical role in the maintenance of
CC       hematopoietic stem cells (By similarity).
CC       {ECO:0000250|UniProtKB:P55265, ECO:0000250|UniProtKB:Q99MU3}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=adenosine in double-stranded RNA + H(+) + H2O = inosine in
CC         double-stranded RNA + NH4(+); Xref=Rhea:RHEA:10120, Rhea:RHEA-
CC         COMP:13885, Rhea:RHEA-COMP:13886, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:28938, ChEBI:CHEBI:74411,
CC         ChEBI:CHEBI:82852; EC=3.5.4.37;
CC         Evidence={ECO:0000250|UniProtKB:P55265};
CC   -!- SUBUNIT: Homodimer. Homodimerization is essential for its catalytic
CC       activity. Isoform 5 can form heterodimers with ADARB1/ADAR2. Isoform 1
CC       interacts with ILF2/NF45 and ILF3/NF90. Binding to ILF3/NF90 up-
CC       regulates ILF3-mediated gene expression. Isoform 1 and isoform 5 (via
CC       DRBM 3 domain) interact with TNPO1. Isoform 5 (via DRBM domains)
CC       interacts with XPO5. Isoform 1 and isoform 5 can interact with
CC       EIF2AK2/PKR and UPF1. {ECO:0000250|UniProtKB:P55265}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P55265}. Nucleus
CC       {ECO:0000250|UniProtKB:P55265}. Note=Shuttles between the cytoplasm and
CC       nucleus. {ECO:0000250|UniProtKB:P55265}.
CC   -!- TISSUE SPECIFICITY: Detected in brain. {ECO:0000269|PubMed:7862132}.
CC   -!- DOMAIN: The first DRADA repeat binds Z-DNA.
CC       {ECO:0000250|UniProtKB:P55265}.
CC   -!- DOMAIN: The third dsRNA-binding domain (DRBM 3) contains an additional
CC       N-terminal alpha-helix that is part of a bi-partite nuclear
CC       localization signal, together with the sequence immediately C-terminal
CC       to DRBM 3. The presence of DRBM 3 is important to bring together the N-
CC       terminal and the C-terminal part of the bi-partite nuclear localization
CC       signal for import mediated by TNPO1. RNA binding interferes with
CC       nuclear import. {ECO:0000250|UniProtKB:P55265}.
CC   -!- PTM: Sumoylation reduces RNA-editing activity.
CC       {ECO:0000250|UniProtKB:P55265}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U18942; AAA65039.1; -; mRNA.
DR   PIR; I57549; I57549.
DR   RefSeq; NP_112268.1; NM_031006.1.
DR   AlphaFoldDB; P55266; -.
DR   SMR; P55266; -.
DR   BioGRID; 249535; 1.
DR   STRING; 10116.ENSRNOP00000028181; -.
DR   iPTMnet; P55266; -.
DR   PhosphoSitePlus; P55266; -.
DR   PaxDb; 10116-ENSRNOP00000028181; -.
DR   GeneID; 81635; -.
DR   KEGG; rno:81635; -.
DR   UCSC; RGD:71099; rat.
DR   AGR; RGD:71099; -.
DR   CTD; 103; -.
DR   RGD; 71099; Adar.
DR   eggNOG; KOG2777; Eukaryota.
DR   InParanoid; P55266; -.
DR   OrthoDB; 118472at2759; -.
DR   PhylomeDB; P55266; -.
DR   Reactome; R-RNO-75102; C6 deamination of adenosine.
DR   Reactome; R-RNO-77042; Formation of editosomes by ADAR proteins.
DR   Reactome; R-RNO-9833482; PKR-mediated signaling.
DR   PRO; PR:P55266; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0016607; C:nuclear speck; IDA:RGD.
DR   GO; GO:0005730; C:nucleolus; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0044530; C:supraspliceosomal complex; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003726; F:double-stranded RNA adenosine deaminase activity; ISO:RGD.
DR   GO; GO:0003725; F:double-stranded RNA binding; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008251; F:tRNA-specific adenosine deaminase activity; IBA:GO_Central.
DR   GO; GO:0006382; P:adenosine to inosine editing; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0016553; P:base conversion or substitution editing; ISO:RGD.
DR   GO; GO:0098586; P:cellular response to virus; ISO:RGD.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0060216; P:definitive hemopoiesis; ISO:RGD.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISO:RGD.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0061484; P:hematopoietic stem cell homeostasis; ISO:RGD.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0035196; P:miRNA processing; ISO:RGD.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; ISO:RGD.
DR   GO; GO:1900369; P:negative regulation of post-transcriptional gene silencing by regulatory ncRNA; ISO:RGD.
DR   GO; GO:0044387; P:negative regulation of protein kinase activity by regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0001649; P:osteoblast differentiation; ISO:RGD.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; ISS:UniProtKB.
DR   GO; GO:0031054; P:pre-miRNA processing; ISO:RGD.
DR   GO; GO:0035455; P:response to interferon-alpha; ISS:UniProtKB.
DR   GO; GO:0009615; P:response to virus; ISS:UniProtKB.
DR   GO; GO:0070922; P:RISC complex assembly; ISO:RGD.
DR   GO; GO:0006396; P:RNA processing; IBA:GO_Central.
DR   GO; GO:0002566; P:somatic diversification of immune receptors via somatic mutation; ISO:RGD.
DR   CDD; cd19913; DSRM_DRADA_rpt1; 1.
DR   CDD; cd19915; DSRM_DRADA_rpt3; 1.
DR   Gene3D; 3.30.160.20; -; 3.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 2.
DR   InterPro; IPR002466; A_deamin.
DR   InterPro; IPR044456; ADAR1_DSRM_1.
DR   InterPro; IPR044457; ADAR1_DSRM_3.
DR   InterPro; IPR014720; dsRBD_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   InterPro; IPR042371; Z_dom.
DR   PANTHER; PTHR10910:SF107; DOUBLE-STRANDED RNA-SPECIFIC ADENOSINE DEAMINASE; 1.
DR   PANTHER; PTHR10910; EUKARYOTE SPECIFIC DSRNA BINDING PROTEIN; 1.
DR   Pfam; PF02137; A_deamin; 1.
DR   Pfam; PF00035; dsrm; 3.
DR   Pfam; PF02295; z-alpha; 2.
DR   SMART; SM00552; ADEAMc; 1.
DR   SMART; SM00358; DSRM; 3.
DR   SMART; SM00550; Zalpha; 2.
DR   SUPFAM; SSF54768; dsRNA-binding domain-like; 3.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 2.
DR   PROSITE; PS50141; A_DEAMIN_EDITASE; 1.
DR   PROSITE; PS50137; DS_RBD; 3.
DR   PROSITE; PS50139; Z_BINDING; 2.
PE   1: Evidence at protein level;
KW   Antiviral defense; Cytoplasm; DNA-binding; Hydrolase; Immunity;
KW   Innate immunity; Isopeptide bond; Metal-binding; Methylation;
KW   mRNA processing; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   RNA-binding; RNA-mediated gene silencing; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN           1..1175
FT                   /note="Double-stranded RNA-specific adenosine deaminase"
FT                   /id="PRO_0000171776"
FT   DOMAIN          135..201
FT                   /note="Z-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00073"
FT   DOMAIN          243..307
FT                   /note="Z-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00073"
FT   DOMAIN          453..521
FT                   /note="DRBM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          564..632
FT                   /note="DRBM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          672..740
FT                   /note="DRBM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00266"
FT   DOMAIN          832..1167
FT                   /note="A to I editase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   REGION          135..204
FT                   /note="Interaction with Z-DNA"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   REGION          207..239
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          315..384
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          524..561
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          632..652
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          662..671
FT                   /note="N-terminal extension of DRBM 3 and constituent of a
FT                   bi-partite nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   REGION          741..747
FT                   /note="C-terminal extension of DRBM 3 and constituent of a
FT                   bi-partite nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   COMPBIAS        319..362
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        363..381
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        635..652
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        858
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         856
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         912
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   BINDING         982
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00240"
FT   MOD_RES         30
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         42
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99MU3"
FT   MOD_RES         228
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         235
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         564
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         579
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         586
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         754
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         760
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         769
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   MOD_RES         771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   CROSSLNK        368
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        368
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   CROSSLNK        368
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
FT   CROSSLNK        821
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P55265"
SQ   SEQUENCE   1175 AA;  129911 MW;  F5C7B5FFB771168C CRC64;
     MSQGFRGPTG VFPHQTQPCL DPSYEHSKWR YLQPRGSESY LRSFQLQQIE FLKGRLPEAP
     LIGAQTQSLP PFLPGHWPRF PGPPAQGKQP EIWGFPRSVT LRNQGFHIGP PLPPPHSRGP
     PWRGAEGLCS HFQELSISQN PEQKVLNRLE ELGEGKATTA YALARELRTP KKDINRILYS
     LERKGKLHRG VGKPPLWSLV PLSQACTQPP RAVNSDKEVP RGEPDLDSED GDPASDLEGP
     SELLDMAEIK EKICDYLFNV SKSSALNLAK NIGLAKARDV NAVLIDLERQ GDVYREGATP
     PIWYLTDKKR ERLQMKRSTH SGPAATPAAV SEATQSTSFP TCHPPQSGGS SSMATSKRVE
     NGQEPVTKYE SRHEARPGPV RLRPHAYHNG PSRAGYVASE NGPWATDDIP DNLNSIHTAP
     GEFRAIMEMP SFYSPTLPRC SPYKKLTECQ LKNPVSGLLE YAQFTSQTCD FNLIEQSGPS
     HEPRFKFQVV INGREFPPAE AGSKKVAKQD AAVKAMAILL REAKAKDSGQ PEELSNCPME
     EDPEKPAESQ PPSSSATSLF SGKSPVTTLL ECMHKLGNSC EFRLLSKEGP AHDPKFQYCV
     AVGAQTFPSV SAPSKKVAKQ MAAEEAMKAL QEEAANSADD QSGGANTDSL DESVAPNKIR
     RIGELVRYLN TNPVGGLLEY ARSHGFAAEF KLIDQSGPPH EPKFVYQAKV GGRWFPAVCA
     HSKKQGKQDA ADAALRVLIG ESEKAEQLGF AEVTPVTGAS LRRTMLLLSR SPDAHPKTLP
     LTGSTFHDQI AMLSHRCFNA LTNSFQPSLL GRKILAAIIM KRDPEDMGVV VSLGTGNRCV
     KGDSLSLKGE TVNDCHAEII SRRGFIRFLY SELMKYNHHT AKNSIFELAR GGEKLQIKKT
     VSFHLYISTA PCGDGAHFDK SCSDRAVEST ESRHYPVFEN PKQGKLRTKV ENGEGTIPVE
     SSDIVPTWDG IRLGERLRTM SCSDKILRWN VLGLQGALLT HFLQPVYLKS VTLGYLFSQG
     HLTRAICCRV TRDGNAFEDG LRYPFIVNHP KVGRVSVYDS KRQSGKTKET SVNWCLADGY
     DLEILDGTRG TVDGPGKELS RVSKKNIFLQ FKKLCSFRAR RDLLQLSYGE AKKAARDYDL
     AKNYFKKSLR DMGYGNWISK PQEEKNFYLC PVPND
//
